호르몬 대체요법 시장 규모는 2024-2030년의 예측 기간 중 CAGR 6.48%로 성장할 것으로 예측됩니다. 호르몬 대체요법(HRT) 시장은 갱년기 장애 및 골다공증과 같은 호르몬 질환 및 표적 질환의 유병률 증가와 더불어 노인 인구 증가가 호르몬 대체요법(HRT)에 대한 수요를 견인하며 큰 성장을 보이고 있습니다. 갱년기 관리에 대한 인식 증가, 노화 방지 및 생식주기 요법을 포함한 재생의료에 대한 관심 증가, 의약품 승인 급증, 제품 출시 및 주요 시장 기업의 존재는 호르몬 대체요법(HRT) 시장의 역동적인 특성을 강조하며 2024-2030년 상당한 성장이 예상되고 있습니다. 강조하고 있습니다.
호르몬 대체 요법 시장을 주도하는 중요한 요소 중 하나는 전 세계에서 폐경기 관리에 대한 여성들의 인식이 높아지고 있다는 점입니다.
여성 폐경기의 세계 평균 연령은 약 50세입니다. 여성의 에스트로겐과 프로게스테론 생산 수준은 50세 이후에 현저하게 감소합니다. 뇌하수체는 난포자극호르몬(FSH)의 생산을 증가시켜 에스트로겐과 프로게스테론의 생산량 감소를 보충합니다. 이는 여성의 경우 안면홍조와 같은 폐경 후 증상으로 신체적으로 나타납니다. 세계보건기구(WHO)가 2022년 발표한 자료에 따르면 2021년에는 50세 이상 여성이 전 세계 여성과 여아의 26%를 차지할 것으로 예상됩니다. 전 세계에서 50세 여성의 부담이 증가하면 결국 전체 폐경기의 부담이 증가하여 피부 홍조, 발한, 심계항진 등 폐경기를 관리하는 데 사용되는 호르몬 대체 요법에 대한 수요가 증가하게 됩니다.
또한 호르몬 균형 장애를 치료하는 새로운 치료제를 발견하기 위한 주요 기업의 연구개발 활동과 제품 허가 증가는 예측 기간 중 연구 시장의 성장을 가속할 것으로 예상됩니다. 새로운 치료법을 확장하는 데 있으며, 주요 기업의 기여도가 증가하면 시장에서 신제품 출시가 더욱 촉진될 것입니다.
세계의 호르몬 대체요법 시장에 대해 조사했으며, 시장의 개요와 치료법별, 적응증별, 투여 경로별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others), Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others), Route of Administration (Oral, Parenteral, and Transdermal), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing burden of menopause, thyroid disorder, osteoporosis, male hypogonadism, along with the increasing research and development activities in hormone replacement therapy, among others across the globe
The hormone replacement therapy is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030. The hormone replacement therapy (HRT) market is experiencing significant growth, driven by the increasing prevalence of hormonal and targeted diseases like menopause and osteoporosis, along with an expanding geriatric population, which is driving the demand for hormone replacement therapy (HRT). Rising awareness about menopause management and interest in regenerative medicines, including anti-aging and reproductive cycle therapies, the surge in drug approvals, product launches, and the presence of key market players highlight the dynamic nature of the HRT market, which is projected to grow substantially from 2024 to 2030.
Hormone Replacement Therapy Market Dynamics:
One of the key aspect driving the hormone replacement therapy market is the rising awareness among women about the management of menopausal issues, across the globe.
The global average age for menopause onset in women is around 50 years. Women's estrogen and progesterone production levels decrease significantly after the age of 50. The pituitary gland compensates for the decrease in estrogen and progesterone production by increasing the production of follicle-stimulating hormone (FSH). This manifests physically in women as post-menopausal symptoms such as flushing and others. According to data published in 2022 by the World Health Organization (WHO), it was stated that, in 2021, women aged 50 and over accounted for 26% of all women and girls globally. The increasing burden of women aged 50 across the globe will ultimately increase the overall menopausal load, thereby increasing the demand for hormonal replacement therapy used in the management of menopausal issues such as flushing of the skin, perspiration, and palpitations, among others.
Additionally, the growing R&D activities by key players for the discovery of novel therapeutics to treat hormonal imbalances and rising product approvals are expected to aid in the growth of the studied market over the forecast period. The increasing contribution of key players in the expansion of novel therapies further drives the introduction of new products in the market. For instance, in January 2022, Ascendis Pharma A/S received European Commission's market authorization for its drug SKYTROFA for the treatment of children and adolescents suffering from growth hormone disorders. This product is the first once-weekly treatment for growth hormone deficiency in the pediatric population.
Also, in June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Therefore, the interplay of all the factors mentioned above collectively will drive the overall hormone replacement therapy market throughout the forecast period from 2024 to 2030.
However, the high cost of drug development, side effects associated with hormone replacement therapy, and the timeline of the stringent regulatory approval process may prove to be challenging factors for hormone replacement therapy market growth.
Hormone Replacement Therapy Market Segment Analysis:
Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others), Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others), Route of Administration (Oral, Parenteral, and Transdermal), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the indication segment of the hormone replacement therapy market, the menopause category is expected to have a significant revenue share in 2023. This is primarily owing to the increasing prevalence of menopause in women across the globe, increasing product launches, strategic investments, and other activities by key players in this category which will aid in driving the market growth during the forecast period.
The rising number of women aged 50 and above will increase the overall burden of menopausal-related issues thereby increasing the demand for various HRT. For instance, combination therapy of levonorgestrel releasing-intrauterine system (LNG-IUS) with oral or percutaneous estrogen, low-dose combined oral contraceptives (COCs), and estrogen-progestogen therapy (EPT) is usually suggested for treating the symptoms of menopause during the menopausal transition. Thus, the increasing burden of women aged 50 and above will lead to an increase in the number of menopausal issues across the globe, ultimately leading to the increased demand for menopausal hormone replacement therapy.
Moreover, the presence of a robust number of menopausal issues treating hormonal replacement therapy in the pipeline will also drive market growth. For example, nearly 20 drugs are currently under clinical trial, which may create a profitable opportunity for the key players in the upcoming years.
Further, various other strategic steps by the key players in the market will help in increasing the demand for hormone replacement therapy. For instance, in June 2022, Astellas Pharma Inc. announced that a New Drug Application (NDA) for fezolinetant had been submitted to the U.S. Food and Drug Administration (FDA). Fezolinetant is an investigational oral, non-hormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.
Also, in September 2021, Theramex announced the approval of Bijuva/Bijuve across Europe and the UK. Bijuva, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and at least 12 months since last menses, combines estradiol and progesterone in a single daily oral capsule.
Therefore, owing to all the above-mentioned factors, the demand for menopausal treating hormone replacement drugs is expected to surge, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the hormone replacement therapy market during the forecast period.
North America is expected to dominate the overall hormone replacement therapy market:
Among all the regions, North America is expected to dominate the hormone replacement therapy market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030.
This can be ascribed to the increasing demand for hormone replacement drugs among women in the region owing to the increasing prevalence of menopausal-related issues. Further, the rising prevalence of growth deficiency disease, thyroid disorder, osteoporosis, hypogonadism, surging research and developmental activities in the region, presence of key domicile players in the region, and others are the key factors that contribute to the growth of the hormone replacement therapy market in North America region during the forecast period from 2024 to 2030.
For instance, as per the recent data from a study conducted by the American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and around 20 million Americans have some form of thyroid disease annually. Also, as per the U.S. Department of Health and Human Services, it was reported that in 2022 nearly 43,800 new cases of thyroid cancer were diagnosed in the US. During thyroid cancer, physicians may prescribe thyroid hormone therapy to prevent the cancer cells from growing. Thus, the increasing prevalence of thyroid-related issues in the US will ultimately upsurge the demand for hormone replacement therapy in the region.
Further, major product launches, collaborative agreements between manufacturers, favorable reimbursement policies in the region, and others are factors responsible for the market growth in the region. For instance, in June 2023, Pfizer Inc. announced that DUAVEE(R) (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy, was back in stock in the United States following a voluntary recall, relaunching it with improved packaging.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the hormone replacement therapy market in the North American region.
Hormone Replacement Therapy Market key Players:
Some of the key market players operating in the hormone replacement therapy market include Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.
Recent Developmental Activities in the Hormone Replacement Therapy Market:
Key Takeaways from the Hormone Replacement Therapy Market Report Study
Target audience who can be benefited from this Hormone Replacement Therapy Market Report Study
Frequently Asked Questions for the Hormone Replacement Therapy Market:
Hormone replacement therapy (HRT) is a treatment technique for replacing and/or replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body.
The hormone replacement therapy is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030.
The hormone replacement therapy (HRT) market is experiencing significant growth, owing to the increasing prevalence of hormonal and targeted diseases like menopause and osteoporosis, along with an expanding geriatric population, which is driving the demand for hormone replacement therapy (HRT). Rising awareness about menopause management and interest in regenerative medicines, including anti-aging and reproductive cycle therapies, the surge in drug approvals, product launches, and the presence of key market players highlight the dynamic nature of the HRT market, which is projected to grow substantially from 2024 to 2030.
Some of the key market players operating in hormone replacement therapy market include Abbott., Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.
Among all the regions, North America is estimated to hold a significant revenue share in the hormone replacement therapy market. This can be ascribed to the increasing demand for hormone replacement drugs among women in the region owing to the increasing prevalence of menopausal-related issues. Further, the rising prevalence of growth deficiency disease, thyroid disorder, osteoporosis, hypogonadism, surging research and developmental activities in the region, presence of key domicile players in the region, and others are the key factors that contribute to the growth of the hormone replacement therapy market in North America region during the forecast period from 2024 to 2030.